Compare iShares MSCI South Africa ETF (EZA) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Africa ETF vs Sana Biotechnology Inc — how do they compare? iShares MSCI South Africa ETF trades at $68.53, while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: iShares MSCI South Africa ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| EZA | SANA | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $81.60 | $5.92 |
52-Week Low | $56.57 | $2.68 |
Market Cap | — | $1.13B |
Enterprise Value | — | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EZA trades at $68.33, down 2.01% today, with a bullish technical bias from moving averages but bearish oscillators. Key support is at $68 and resistance at $70. The company has a dividend scheduled for June 2026, but financial ratios like P/E and P/S are not provided in the data.
Outlook is mixed: technical strength contrasts with macroeconomic headwinds highlighted in recent news. Risks include exposure to South African sectors sensitive to interest rates and commodities. Investment appeal hinges on navigating these challenges amid a bullish trend signal.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI South Africa ETF
EZA is a country-specific ETF that tracks the South African equity market. It provides exposure to large and mid-cap companies across key sectors like materials and financials, with top holdings such as AngloGold Ashanti and Naspers.
Read more on EZA →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
